Technical Analysis for CGEN - Compugen Ltd.

Grade Last Price % Change Price Change
D 1.71 6.88% 0.11
CGEN closed up 6.88 percent on Friday, November 1, 2024, on 85 percent of normal volume.
Earnings due: Nov 5
*** please verify all earnings dates ***
1 Watcher
Watchlist Portfolio

Trend Table & Recent EOD Trading Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent Down Down Up

Date Alert Name Type % Chg
Crossed Above 20 DMA Bullish 0.00%
MACD Bullish Signal Line Cross Bullish 0.00%
Bollinger Band Squeeze Range Contraction 0.00%
BB Squeeze + Lower Band Touch Range Contraction 0.00%
Gapped Up Strength 0.00%
Lower Bollinger Band Touch Weakness 0.00%
Bollinger Band Squeeze Range Contraction 6.88%
Stochastic Reached Oversold Weakness 6.88%
BB Squeeze + Lower Band Touch Range Contraction 6.88%
Below Lower BB Weakness 6.88%

   Recent Intraday Alerts

Alert Time
20 DMA Resistance about 21 hours ago
Rose Above 20 DMA about 21 hours ago
10 DMA Resistance about 23 hours ago
Up 5% about 23 hours ago
Rose Above 10 DMA about 23 hours ago

Free Daily (Stock) Chart Reading

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

Compugen Ltd. Description

Compugen Ltd., a therapeutic product discovery company, engages in the research, development, and commercialization of therapeutic and diagnostic biomarker product candidates primarily in the United States, Europe, and Israel. It focuses on the therapeutic proteins and monoclonal antibodies to address unmet needs in the fields of immunology and oncology. The company's therapeutic proteins pipeline includes CGEN-15001, a novel protein for the treatment of autoimmune disorders; CGEN-15021, a novel fusion protein for the treatment of multiple sclerosis, rheumatoid arthritis, and other autoimmune diseases; CGEN-15091, a novel fusion protein for the treatment of multiple sclerosis and autoimmune diseases; CGEN-15031, a fusion protein candidate to treat multiple sclerosis; and CGEN-15051, a fusion protein candidate for the treatment of rheumatoid arthritis. Its monoclonal antibody therapy product candidates include CGEN-15001T, a membrane protein target for the treatment of cancer; CGEN-15022 membrane protein for the treatment of multiple cancers; CGEN-671, a novel drug target for the treatment of multiple epithelial tumors; and CGEN-928 drug target for the treatment of multiple myeloma. Compugen Ltd. was founded in 1993 and is headquartered in Tel Aviv, Israel.


Classification

Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Biopharmaceutical Cancer Life Sciences Immunology Autoimmune Disease Antibodies Treatment Of Cancer Monoclonal Antibodies Monoclonal Antibody Antibody Therapeutic Products Autoimmunity Biomarkers Multiple Sclerosis Rheumatoid Arthritis Multiple Myeloma Autoimmune Disorders Immune Disorders Fusion Protein Compugen Monoclonal Antibody Therapy Treatment Of Multiple Sclerosis Antibody Therapy

Is CGEN a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 3.0301
52 Week Low 0.53
Average Volume 203,639
200-Day Moving Average 2.05
50-Day Moving Average 1.82
20-Day Moving Average 1.70
10-Day Moving Average 1.68
Average True Range 0.08
RSI (14) 48.45
ADX 14.05
+DI 20.72
-DI 21.35
Chandelier Exit (Long, 3 ATRs) 1.74
Chandelier Exit (Short, 3 ATRs) 1.83
Upper Bollinger Bands 1.77
Lower Bollinger Band 1.62
Percent B (%b) 0.58
BandWidth 9.13
MACD Line -0.04
MACD Signal Line -0.04
MACD Histogram 0.0015
Fundamentals Value
Market Cap 151.04 Million
Num Shares 88.3 Million
EPS -0.37
Price-to-Earnings (P/E) Ratio -4.62
Price-to-Sales 25.20
Price-to-Book 3.55
PEG Ratio 0.00
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 1.89
Resistance 3 (R3) 1.87 1.80 1.86
Resistance 2 (R2) 1.80 1.75 1.81 1.85
Resistance 1 (R1) 1.75 1.72 1.78 1.77 1.84
Pivot Point 1.68 1.68 1.69 1.69 1.68
Support 1 (S1) 1.63 1.63 1.66 1.65 1.58
Support 2 (S2) 1.56 1.60 1.57 1.57
Support 3 (S3) 1.51 1.56 1.56
Support 4 (S4) 1.53